Letizia Porcelli

List of Publications by Year
in descending order

69	1,685	279798	302126
papers	citations	23 h-index	39 g-index

72	72	72	3574
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The ERRÎ±â€“VDR axis promotes calcitriol degradation and estrogen signaling in breast cancer cells, while VDRâ€CYP24A1â€ERRÎ± overexpression correlates with poor prognosis in patients with basalâ€like breast cancer. Molecular Oncology, 2022, 16, 904-920.	4.6	10
2	Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma. Molecular Cancer, 2022, 21, 20.	19.2	55
3	Microfluidic-Assisted Preparation of Targeted pH-Responsive Polymeric Micelles Improves Gemcitabine Effectiveness in PDAC: In Vitro Insights. Cancers, 2022, 14, 5.	3.7	12
4	BRAFV600E;K601Q metastatic melanoma patient-derived organoids and docking analysis to predict the response to targeted therapy. Pharmacological Research, 2022, 182, 106323.	7.1	8
5	Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib. Biomedicine and Pharmacotherapy, 2021, 133, 111006.	5.6	16
6	Long Non-Coding RNA Landscape in Prostate Cancer Molecular Subtypes: A Feature Selection Approach. International Journal of Molecular Sciences, 2021, 22, 2227.	4.1	2
7	The Interaction between Reactive Peritoneal Mesothelial Cells and Tumor Cells via Extracellular Vesicles Facilitates Colorectal Cancer Dissemination. Cancers, 2021, 13, 2505.	3.7	9
8	uPAR⁺ extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients. , 2021, 9, e002372.		23
9	Behind the Scene: Exploiting MC1R in Skin Cancer Risk and Prevention. Genes, 2021, 12, 1093.	2.4	15
10	Microfluidic preparation and in vitro evaluation of iRGD-functionalized solid lipid nanoparticles for targeted delivery of paclitaxel to tumor cells. International Journal of Pharmaceutics, 2021, 610, 121246.	5.2	23
11	Tomatine Displays Antitumor Potential in In Vitro Models of Metastatic Melanoma. International Journal of Molecular Sciences, 2020, 21, 5243.	4.1	18
12	The Role of Non-Coding RNAs as Prognostic Factor, Predictor of Drug Response or Resistance and Pharmacological Targets, in the Cutaneous Squamous Cell Carcinoma. Cancers, 2020, 12, 2552.	3.7	16
13	Hydroxy-Propil-Î²-Cyclodextrin Inclusion Complexes of two Biphenylnicotinamide Derivatives: Formulation and Anti-Proliferative Activity Evaluation in Pancreatic Cancer Cell Models. International Journal of Molecular Sciences, 2020, 21, 6545.	4.1	4
14	The Î²-adrenergic receptor antagonist propranolol offsets resistance mechanisms to chemotherapeutics in diverse sarcoma subtypes: a pilot study. Scientific Reports, 2020, 10, 10465.	3.3	18
15	Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function. Journal of Cellular Physiology, 2020, 235, 8085-8097.	4.1	7
16	Abstract 2238: Synergistic effect of sunitinib and PD-1 inhibitor nivolumab on colorectal cancerin vitroandin vivo. , 2020, , .		0
17	Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study. Cancers, 2019, 11, 942.	3.7	66
18	Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells. Scientific Reports, 2019, 9, 4099.	3.3	112

#	Article	IF	Citations
19	CAFs and TGF-Î² Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer. Cancers, 2019, 11, 330.	3.7	71
20	Synthesis and biological evaluation of N-biphenyl-nicotinic based moiety compounds: A new class of antimitotic agents for the treatment of Hodgkin Lymphoma. Cancer Letters, 2019, 445, 1-10.	7.2	7
21	Sorafenib delivery nanoplatform based on superparamagnetic iron oxide nanoparticles magnetically targets hepatocellular carcinoma. Nano Research, 2017, 10, 2431-2448.	10.4	54
22	Targeting human liver cancer cells with lactobionic acid-G(4)-PAMAM-FITC sorafenib loaded dendrimers. International Journal of Pharmaceutics, 2017, 528, 485-497.	5.2	57
23	Potential therapeutic combination of beta-blockers and trabectedin in metastatic soft tissue sarcoma and ovarian cancer. Annals of Oncology, 2017, 28, vi66-vi67.	1.2	0
24	Grape seed extracts modify the outcome of oxaliplatin in colon cancer cells by interfering with cellular mechanisms of drug cytotoxicity. Oncotarget, 2017, 8, 50845-50863.	1.8	9
25	Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma. OncoTargets and Therapy, 2016, Volume 9, 4681-4686.	2.0	9
26	Synthesis, Characterization, and Cytotoxicity of the First Oxaliplatin Pt(IV) Derivative Having a TSPO Ligand in the Axial Position. International Journal of Molecular Sciences, 2016, 17, 1010.	4.1	19
27	Probing the interaction between cisplatin and the therapeutic monoclonal antibody trastuzumab. RSC Advances, 2016, 6, 29229-29236.	3.6	4
28	Detrimental effects of melanocortinâ€1 receptor (<scp>MC</scp>1R) variants on the clinical outcomes of <scp>BRAF</scp> V600 metastatic melanoma patients treated with <scp>BRAF</scp> inhibitors. Pigment Cell and Melanoma Research, 2016, 29, 679-687.	3.3	8
29	New insight into the role of metabolic reprogramming in melanoma cells harboring BRAF mutations. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 2710-2718.	4.1	27
30	Hepatic stellate cells induce hepatocellular carcinoma cell resistance to sorafenib through the laminin‐332/α3 integrin axis recovery of focal adhesion kinase ubiquitination. Hepatology, 2016, 64, 2103-2117.	7.3	80
31	Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer. World Journal of Gastroenterology, 2016, 22, 6287.	3.3	8
32	Mast Cells (MCs) Infiltration Affects Pancreatic Cancer (PC) Response To Gemcitabine Based Chemotherapy: In Vitro New Insights. Annals of Oncology, 2015, 26, vi101.	1.2	0
33	Possible predictive role of the soluble cd40 ligand (scd40l) in metastatic pancreatic ductal adenocarcinoma (PDAC) patients (pts) treated with first line folfirinox or gemcitabine/nab-paclitaxel combination. Annals of Oncology, 2015, 26, vi99.	1.2	0
34	Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy. Journal of Translational Medicine, 2015, 13, 26.	4.4	34
35	Metastatic melanoma cells with BRAF G469A mutation: nab-paclitaxel better than vemurafenib?. Cancer Chemotherapy and Pharmacology, 2015, 76, 433-438.	2.3	9
36	Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer. Cell Death and Disease, 2014, 5, e1076-e1076.	6.3	17

#	Article	IF	Citations
37	Irradiation-induced angiosarcoma and anti-angiogenic therapy: A therapeutic hope?. Experimental Cell Research, 2014, 321, 240-247.	2.6	21
38	844: A novel strategy for the treatment of Hodgkin lymphoma. European Journal of Cancer, 2014, 50, S205.	2.8	0
39	P74 LAMININ-5 INDUCES RESISTANCE TO SORAFENIB IN HCC PRECLINICAL MODELS. Journal of Hepatology, 2014, 60, S91.	3.7	0
40	New Vascular Disrupting Agents in Upper Gastrointestinal Malignancies. Current Medicinal Chemistry, 2014, 21, 1039-1049.	2.4	7
41	The EGFR Pathway Regulates BCRP Expression in NSCLC Cells: Role of Erlotinib. Current Drug Targets, 2014, 15, 1322-1330.	2.1	23
42	Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity. Molecular Oncology, 2013, 7, 308-322.	4.6	54
43	Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors. Current Pharmaceutical Design, 2013, 19, 918-926.	1.9	9
44	Synthetic Lethality to Overcome Cancer Drug Resistance. Current Medicinal Chemistry, 2012, 19, 3858-3873.	2.4	18
45	275 SORAFENIB EFFECTIVENESS IS INHIBITED IN PRESENCE OF LAMININ-5 IN HCC CELLS. Journal of Hepatology, 2012, 56, S114.	3.7	1
46	Synthesis, Characterization and Biological Evaluation of Ureidofibrate-Like Derivatives Endowed with Peroxisome Proliferator-Activated Receptor Activity. Journal of Medicinal Chemistry, 2012, 55, 37-54.	6.4	46
47	Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer. British Journal of Cancer, 2011, 104, 769-780.	6.4	52
48	The Impact of Folate Status on the Efficacy of Colorectal Cancer Treatment. Current Drug Metabolism, 2011, 12, 975-984.	1.2	19
49	The Coordinated Role of CYP450 Enzymes and P-gp in Determining Cancer Resistance to Chemotherapy. Current Drug Metabolism, 2011, 12, 713-721.	1.2	17
50	MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment. European Journal of Pharmacology, 2011, 670, 74-84.	3.5	10
51	EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence. Frontiers in Bioscience - Landmark, 2011, 16, 1962.	3.0	42
52	Nti-EGFR monoclonal antibody in cancer treatment: in vitro and in vivo evidence. Frontiers in Bioscience - Landmark, 2011, 16, 1973.	3.0	7
53	Possibile role of vascular endothelial growth factor (VEGF) levels in immunodepleted plasma of metastatic colorectal cancer (mCRC) patients (pts) treated with a biweekly administration of capecitabine plus oxaliplatin (XELOX-2) plus bevacizumab: Preliminary results.. Journal of Clinical Oncology, 2011, 29, e14155-e14155.	1.6	1
54	Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences. Cancer Chemotherapy and Pharmacology, 2010, 65, 335-346.	2.3	45

#	Article	IF	Citations
55	p53 as the main traffic controller of the cell signaling network. Frontiers in Bioscience - Landmark, 2010, 15, 1172.	3.0	12
56	34 AZD1152 PLUS GEMCITABINE FOR PANCREAS CANCER TREATMENT: IN VITRO AND IN VIVO STUDY. Cancer Treatment Reviews, 2010, 36, S105.	7.7	0
57	46 IS BCRP EXPRESSION AND LOCALIZATION REGULATED BY EGFR PATHWAY IN NSCLC CELLS?. Cancer Treatment Reviews, 2010, 36, S108.	7.7	0
58	47 BIOLOGICAL CHARACTERIZATION OF MC70, AS POTENT INHIBITOR OF ABC TRANSPORTERS INVOLVED IN MULTIDRUG RESISTANCE. Cancer Treatment Reviews, 2010, 36, S109.	7.7	0
59	Intracellular Trafficking of MDR Transporters and Relevance of SNPs. Current Topics in Medicinal Chemistry, 2009, 9, 197-208.	2.1	25
60	Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorganic and Medicinal Chemistry, 2008, 16, 362-373.	3.0	78
61	Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells. Biochemical Pharmacology, 2008, 75, 1035-1044.	4.4	47
62	EGFR and VEGFR as potential target for biological therapies in HCC cells. Cancer Letters, 2008, 262, 257-264.	7.2	48
63	Validation of gefitinib effectiveness in a broad panel of head and neck squamous carcinoma cells. International Journal of Molecular Medicine, 2008, 21, 809-17.	4.0	3
64	257 An inhibitor of VEGF(ZD6474) as a potential new drug for HCC: A preclinical study. Journal of Hepatology, 2006, 44, S102.	3.7	0
65	ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells. Biochemical Pharmacology, 2006, 71, 479-485.	4.4	36
66	Cyclohexylpiperazine derivative PB28, a Ïƒ2 agonist and Ïƒ1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer. Molecular Cancer Therapeutics, 2006, 5, 1807-1816.	4.1	108
67	Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressaâ„¢) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects. World Journal of Gastroenterology, 2006, 12, 5140.	3.3	25
68	Laminin-5 offsets the efficacy of gefitinib (â€˜Iressaâ€™) in hepatocellular carcinoma cells. British Journal of Cancer, 2004, 91, 1964-1969.	6.4	50
69	The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressaâ„¢, ZD1839). Biochemical Pharmacology, 2004, 68, 135-144.	4.4	54